Physician profile
Andre T Bobo
NPI 1437299724
$1,148.01
in general payments reported to CMS, 2019-2025
16 companies · $86.40 in 2025
The $86.40 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $464 · 2020: $84.02 · 2021: $305 · 2022: $136 · 2023: $38.44 · 2024: $33.90 · 2025: $86.40.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $159.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $158.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $360.25 | 2019-2022 | |
| Allergan, INC. | $229.71 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $120.73 | 2019 | |
| Daiichi Sankyo INC. | $92.19 | 2019-2020 | |
| Biogen, INC. | $86.40 | 2025 | Zurzuvae |
| Mayne Pharma Commercial LLC | $64.00 | 2021-2022 | |
| Sumitomo Pharma America, INC. | $33.90 | 2024 | Myfembree |
| Merck Sharp & Dohme LLC | $25.56 | 2019 | |
| Agile Therapeutics, INC. | $23.31 | 2021 | |
| Medtronic, INC. | $22.25 | 2022 | |
| Pfizer INC. | $20.05 | 2023 | |
| Alnylam Pharmaceuticals INC. | $18.39 | 2023 | Givlaari |
| Myovant Sciences INC. | $15.42 | 2022 | |
| Lupin INC. | $12.31 | 2019 | |
| Avion Pharmaceuticals | $11.93 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evofem Biosciences, INC. | $11.61 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andre Bobo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.